Sign in
Taking peopleNo phase

Iron, erythropoietin and vitamin C for anaemia before heart surgery

Tests iron sucrose with erythropoietin and ascorbic acid for anaemia in heart surgery patients.

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Effect of the Combined Programme on Perioperative Anaemia(CPPA)
Status
Recruiting
People taking part
110 people, planned
Started
15 Mar 2023
Planned end
1 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Iron Sucrose, recombinant human erythropoietin, ascorbic acid
  • conventional treatment
Record updated
10 January 2025

Who can take part

The trial is looking for adults with anaemia and low iron who are having planned major heart surgery (valve replacement, CABG bypass surgery or both).

Age
18 years and above
Sex
All sexes can join
Disease stage
Planned (not emergency) major heart surgery. Anaesthesia risk grade ASA 1-3. Haemoglobin (Hb) between 90 and 130 g/L in men, or between 90 and 120 g/L in women.
Earlier treatment
No iron, blood transfusion or other anaemia treatment within 12 weeks before surgery.
Biomarker or test result
Ferritin <300µg/L and transferrin saturation <25%.
Main reasons for not taking part
  • Allergy or other reason you cannot take iron sucrose, recombinant human erythropoietin or ascorbic acid
  • Pregnancy or breastfeeding, or weight ≤ 50 kg (110 lb)
  • Chronic kidney problems, urinary stones, oxalate deposits, gout, or chronic liver disease or liver tests 3 times or more above the upper normal limit
  • Iron overload, family history of haemochromatosis or thalassaemia, transferrin saturation > 50%, or other causes of anaemia such as folic acid or vitamin B12 deficiency
  • Emergency surgery, temperature >37.5 °C (99.5 °F) before surgery, or taking antibiotics for an infection rather than for prevention
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Age 18 years and above
  • Ferritin <300µg/L, transferrin saturation <25%, male 90<Hb<130g/L or female 90<Hb<120g/L
  • Elective major cardiac surgery (valve replacement, CABG coronary artery bypass surgery or a combination of both)
  • ASA: Grade 1-3
  • Signed informed consent

Who cannot take part

  • Emergency surgery
  • Use of iron, blood transfusion or related anaemia treatment within 12 weeks prior to surgery; Withdrawal criteria:
  • Cancellation of surgery
  • Allergy or contraindication to iron sucrose or recombinant human erythropoietin or ascorbic acid
  • Presence of chronic renal insufficiency, urinary stones, oxalate deposits, gout
  • Chronic liver disease and/or screening alanine transferase/aspartate transferase above normal 3 times or more above the upper limit of the normal range
  • Family history of haemochromatosis, thalassaemia or transferrin saturation > 50%
  • Known history of iron overload
  • Patients with a preoperative temperature >37.5 °C or on non-prophylactic antibiotics
  • Pregnancy or breastfeeding stage
  • weight ≤ 50 kg
  • Other known causes of anaemia (folic acid or vitamin B12 deficiency or haemoglobinopathies, etc.)
  • massive blood transfusion (≥ 10 red blood cells (RBC)/24h)
  • Preoperative interventions not performed according to standard

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Cardiac surgery or iron deficiency anemia

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

We used the preoperative intervention of iron sucrose in combination with human erythropoietin and vitamin C as an innovative combination therapy. This combined treatment strategy aims to improve perioperative anaemia in patients by promoting erythropoiesis and improving iron metabolism. Compared with previous perioperative intravenous iron supplementation, this innovative combination therapy strategy takes into account multiple aspects of iron metabolism as well as the biological mechanisms of erythropoiesis, providing a more comprehensive intervention. Management of perioperative anaemia in previous studies has largely relied on single intravenous iron supplementation therapy, and although this approach has been effective in raising iron levels, its effectiveness may be limited in patients who have impaired iron utilisation or in situations where concurrent stimulation of erythropoiesis is required. The use of iron sucrose in combination with human erythropoietin and vitamin C, on the other hand, is based on an integrative therapeutic concept aimed at providing a more comprehensive response to perioperative anaemia by simultaneously promoting effective iron utilisation and erythropoiesis.

The 2 groups in the trial

  • Iron treatment intervention armTreatment being tested

    The combination therapy group will receive three treatments consisting of 200 mg/100 ml of iron sucrose IV infusion, 150 IU/Kg of erythropoietin subcutaneously and 2 mg/100 ml of vitamin C IV infusion in the week prior to surgery

    Treatment: Iron Sucrose, recombinant human erythropoietin, ascorbic acid

  • conventional treatment armExisting treatment, for comparison

    Treatment in accordance with measures routinely used by the surgeon's team to treat anemia including but not limited to (clinical observation, oral iron supplementation, intravenous iron supplementation, blood transfusion, or other measures) will be documented faithfully by the study team

    Treatment: conventional treatment

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effectiveness of Iron Sucrose Combined With rHuEPO and Ascorbic Acid in Improving Perioperative Anaemia in Patients Undergoing Major Cardiac Surgery
Plain-language title
Iron, erythropoietin and vitamin C for anaemia before heart surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT05353348, who can take part
Record updated
10 January 2025